Androgen-regulated gene expressed in prostate tissue

• US 6,566,130 B1
• Filed: 01/26/2001
• Issued: 05/20/2003
• Est. Priority Date: 01/28/2000
• Status: Expired due to Term

• Current Assignee: Henry M Jackson Foundation For The Advancement of Military Medicine Incorporated
• Original Assignee: Henry M Jackson Foundation For The Advancement of Military Medicine Incorporated
• Inventors: Xu, Linda L., Segawa, Takehiko, Srivastava, Shiv, Moul, Judd W.
• Primary Examiner(s): Myers, Carla J.
• Assistant Examiner(s): Sakelaris, Sally
• Application Number:
  US09/769,482
• Time in Patent Office: 844 Days
• Field of Search: 435/6, 435/69.1, 435/320.1, 435/325, 435/252.3, 536/23.5
• US Class Current: 435/325
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

This invention relates to androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.

Claims

1. An isolated nucleic acid molecule selected from:

(a) the polynucleotide sequence of SEQ ID NO;

2;

or

(b) an isolated nucleic acid molecule that encodes a polypeptide having an amino acid sequence of SEQ ID NO;

3.

2. A recombinant vector comprising the nucleic acid molecule of claim 1.

3. A host cell comprising the vector of claim 2.

4. The host cell of claim 3 selected from bacterial cells, yeast cells, or animal cells.